THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Repatha® (evolocumab) can be used to help adults at increased risk for major adverse cardiovascular events lower their LDL-C ...
Conquering cholesterol is one of the biggest challenges facing cardiovascular disease patients, and a new study conducted by Amgen Inc. (NASDAQ: AMGN) shows that its cholesterol-busting drug Repatha ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
March 27 (Reuters) - Amgen Inc's (AMGN.O), opens new tab battle with Sanofi (SASY.PA), opens new tab and Regeneron (REGN.O), opens new tab at the U.S. Supreme Court over its cholesterol drug Repatha ...
(HealthDay News) — Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration, the second non-statin drug in its class approved to treat high cholesterol. The injected drug, among ...
THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback